Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Covered in this story
Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.